Polysaccharide and monosaccharide guided liver delivery of Sorafenib Tosylate – A nano-strategic approach and comparative assessment of hepatospecificity

• Published in: International journal of pharmaceutics 2022-09, Vol.625, p.122039-122039, Article 122039
• Main Authors: Dhawan, V., Lokras, A., Joshi, G., Marwah, M., Venkatraman, M., Mohanty, B., Darshan, K., Chaudhari, P., Warawdekar, U., Saraf, M., Nagarsenker, M.
• Format: Article
• Language: English
• Subjects: Hepatic disposition; Liposomes; Liver targeting; Nanosystem; Polysaccharide; Sorafenib tosylate
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2022.122039

[Display omitted] Hepatospecific delivery by ligand based receptor targeting is an established strategy to augment therapy associated with liver diseases and disorders. Previously, we have investigated the effect of ligand headgroup on cellular uptake mediated by the asialoglycoprotein receptor by in silico and in vitro approach. In this paper, we report the design of agarose based liposomes for delivery to liver cancer cells and provide a proof of concept of the targeting efficiency against galactose liposomes using an in vivo approach. Sorafenib Tosylate loaded targeting liposomes were developed and optimized using factorial design. Comparative evaluation including cell cytotoxicity, pharmacokinetics and biodistribution and hepatospecific uptake was performed for both the liposomal systems. The formulations possessed a particle size of 150 – 180 nm and a zeta potential of 30 - 60 mV depending on the amount of ligand and drug loading, with more than 90% entrapment efficiency. A two-fold increase in cytotoxicity was observed with agarose-based liposomes as compared to galactose based liposomes. In vivo PK evaluation indicated a reduction in half life of drug when loaded in agarose ligand loaded system, probably due to greater uptake in the liver as evidenced in biodistribution study. Intrahepatic disposition revealed a higher PC/NPC uptake ratio with the targeted systems as compared to conventional liposomes, although the agarose-based system resulted in highest uptake ratio. A biocompatible platform for specific delivery of drugs to hepatocytes was established validating a rational approach to design liver targeting systems.